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Abstract
Background: Nitric oxide (NO) is essential for host defense in rodents, but the role of NO during tuberculosis (TB) in man
remains controversial. However, earlier observations that arginine supplementation facilitates anti-TB treatment, supports the
hypothesis that NO is important in the host defense against TB. Local production of NO measured in fractional exhaled air
(FeNO) in TB patients with and without HIV co-infection has not been reported previously. Thus, our aim was to investigate
levels of FeNO in relation to clinical symptoms and urinary NO metabolites (uNO).
Methods: In a cross sectional study, FeNO and uNO were measured and clinical symptoms, chest x-ray, together with serum
levels of arginine, tumor necrosis factor alpha (TNF-alpha) and interleukin 12 (IL-12) were evaluated in sputum smear positive
TB patients (HIV+/TB, n = 36, HIV-/TB, n = 59), their household contacts (n = 17) and blood donors (n = 46) from Gondar
University Hospital, Ethiopia.
Results: The proportion of HIV-/TB patients with an increased FeNO level (> 25 ppb) was significantly higher as compared to
HIV+/TB patients, but HIV+/TB patients had significantly higher uNO than HIV-/TB patients. HIV+ and HIV-/TB patients both
had lower levels of FeNO compared to blood donors and household contacts. The highest levels of both uNO and FeNO were
found in household contacts. Less advanced findings on chest x-ray, as well as higher sedimentation rate were observed in HIV+/
TB patients as compared to HIV-/TB patients. However, no significant correlation was found between FeNO and uNO, chest
x-ray grading, clinical symptoms, TNF-alpha, IL-12, arginine levels or sedimentation rate.
Conclusion: In both HIV negative and HIV co infected TB patients, low levels of exhaled NO compared to blood donors and
household were observed. Future studies are needed to confirm whether low levels of exhaled NO could be a risk factor in
acquiring TB and the relative importance of NO in human TB.
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Background
One third of the world's population is currently infected
with Mycobacterium tuberculosis (Mtb) and about 2 million
people die every year from tuberculosis (TB) [1]. Yet only
5–10% of immunocompetent individuals who are
infected by Mtb develop the disease during their lifetime,
indicating the presence of effective host immunity [2]. In
Africa, HIV is the single most important factor determin-
ing the increased incidence of TB in the past years, under-
lining the synergy between the progress of HIV and TB [3].
The higher risk of HIV patients developing TB could be
related to the fact that macrophages that are not activated
by CD4+ T cells are unable to restrict the growth of Mtb
[4].
Although controversial in humans, nitric oxide (NO) pro-
duced by activated macrophages has anti-mycobacterial
effects in mice [5]. The increased production of NO from
the amino acid arginine in inflammatory cells like macro-
phages is catalyzed by the inducible nitric oxide synthase
[6] and our group has previously shown that supplemen-
tation of arginine during anti-TB chemotherapy improves
clinical outcome in TB patients without HIV co-infection
(HIV-/TB) [7]. NO has a half-life of a few seconds and is
converted to nitrite (NO2
-) and nitrate (NO3
-), two stable
end products of NO metabolism that can be measured in
urine (uNO) [8]. Moreover endogenous NO, produced in
the lower and upper respiratory tract, can be measured in
exhaled air as fractional exhaled NO (FeNO) using a
chemiluminescence NO analyzer [9]. Asthma [10] and
viral respiratory tract infection [11] are associated with
high FeNO while low levels have been described in cystic
fibrosis [12] and HIV-infection [13]. It has been observed
that HIV-/TB patients have an increase in FeNO [14], as
well as elevated levels of uNO [15].
Our aim was to investigate the levels of FeNO in relation
to uNO in sputum smear positive tuberculosis patients
(both HIV+ and HIV-), their household contacts and
healthy blood donors in Gondar, Ethiopia, in order to
investigate local and general production of NO in pulmo-
nary tuberculosis in relation to clinical symptoms and
HIV co-infection.
Methods
Study subjects and design
Patients with newly diagnosed smear positive tuberculosis
(n = 111) were recruited at the Direct Observed Treatment
Short-Course (DOTS) Clinic at Gondar University Hospi-
tal, Ethiopia. The inclusion criteria were age 15–60 years
and AFB (acid fast bacilli) sputum smear positive tubercu-
losis. The exclusion criteria were hospitalization, smok-
ing, pregnancy, or concomitant disease other than HIV.
In the group of household contacts to smear positive TB
patients (HC, n = 21) FeNO was measured, morning urine
was collected and a chest x-ray performed. To be included
the HC should be part of the household and continuously
spend more than 12 h per day together with the TB patient
as well as have a chest x-ray without evidence of active
tuberculosis or other infectious disease. Exclusion criteria
were acute or chronic disease, smoking and antibiotic or
corticosteroid treatment.
A community control group of blood donors (BD, n = 63)
were asked to bring a morning urine sample and FeNO
was measured. Exclusion criteria were antibiotic or corti-
costeroid treatment, cough, smoking or household con-
tact treated for TB. All patients and blood donors were
offered pre and post counseling at the VCT (voluntary
counseling and testing) clinic prior to HIV testing accord-
ing to the hospital routine.
All patients and study subjects were included only after
informed consent. The study was approved by Gondar
College of Medical and Health Sciences, Gondar Univer-
sity, Ethiopia and by the Regional Ethics Review Board,
Linköping, Sweden.
Analysis of urine
Nitrate (NO3
-) and nitrite (NO2
-) were measured in urine
according to the method described by Verdon et al [16]
where nitrate was reduced to nitrite by nitrate reductase
and measured using the Griess reaction. Nicotinamide
adenine dinucleotide phosphate (10 μM, Roche, Bro-
mma, Sweden) was added directly followed by nitrate
reductase (10 U/ml, Roche), glucose-6-phosphate (50
mM, Sigma Chemical CO, St Louis, USA) and glucose-6-
phosphate dehydrogenase (40 U/ml, Sigma) diluted in
phosphate-buffered saline and incubated at room temper-
ature for 45 min. Sulphanilic acid (1%) diluted in phos-
phatic acid (5%) and N-(1-naphtyl) ethylenediamine
(0.1%, Roche) was added and incubated for 10 min
before analyzed in triplicates in an ELISA multi well
reader at 540 nm (Anthos labtech instrument 2001, Aus-
tria).
Fractional exhaled NO
In all TB patients, FeNO was measured before TB treat-
ment was initiated. The study subjects were asked to
inhale a maximum amount of air outside the valve and
exhale into the valve connected to the chemiluminescence
NO analyzer (NIOX, Aerocrine AB, Sweden), approved by
the FDA [9]. The exhalation was visualized on a computer
screen to keep the flow rate between 45–55 ml/s and the
measurement length to 10 s [9]. Dead space-time was set
to 0.5 s. The average of three measurements with the pla-
teau concentration within 2.5 ppb (parts per billion) or
10% was recorded.BMC Infectious Diseases 2008, 8:146 http://www.biomedcentral.com/1471-2334/8/146
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HIV-status
The HIV status of the TB patients was analyzed with
Enzygnost Anti-HIV 1/2 Plus (DADE BEHRING, Ger-
many) and confirmed with Vironistika HIV Uni-Form II
ag/ab (Biomérieux, France) by using an ELISA multi well
reader (Anthos labtech instrument 2001, Austria). The
blood donors were analyzed according to the hospital
routines with Vironistika HIV Uni-Form II ag/ab Microe-
lisa system.
Plasma levels of L-arginine
All plasma samples were filtered by centrifugation at
12,000 × g for 90 min in a Microcon YM-3 tube with a cut-
off of 3 kDa (Amicon Inc., Beverly, USA). Plasma L-
arginine was analyzed using a modified version of the
protocol described by Carlberg [17]. The high-perform-
ance liquid chromatography (HPLC) system consisted of
an Optilab 931 pump (Shimadzu, Tokyo, Japan) and an
RF-535 Fluorescence HPLC monitor (Shimadzu),
equipped with a 5 mm Microsphere C18 column (25064
mm) from Knauer (Berlin, Germany). An excitation/emis-
sion wavelength of 338/425 nm was used. A mobile phase
comprising 20% acetonitrile (Fisher Scientific, Leicester-
shire, UK) in 10 mM KH2PO4 was used at a flow rate of 1
mL·min-1. Precolumn derivatisation of samples was per-
formed with an equal volume of o-pthaldialdehyde rea-
gent solution (Sigma). Levels of plasma L-arginine were
transposed from a standard curve constructed from
known concentrations (Sigma).
Serum levels of TNF-alpha and IL-12
The serum levels of TNF-alpha and IL-12 were analyzed
using commercial ELISA kits (Quantikine HS, R&D Diag-
nostics, USA) according to the instructions from the man-
ufacturer.
Chest x-ray grading
Grading of chest x-ray findings of pulmonary tuberculosis
was done according to the National Tuberculosis Associa-
tion of the USA in normal, minimal, moderately
advanced and far advanced tuberculosis [18]. For statisti-
cal evaluation this grading was translated to a semi quan-
titative scale from 0 (normal) to 3 (far advanced
tuberculosis). The chest x-rays were read by one single
radiologist and reading was blinded for HIV status.
Statistics
Data are presented as median and interquartile range (25–
75%). To compare groups the Mann-Whitney test was
used and correlations were tested with Pearson's correla-
tion test (r2). A p-value of ≤ 0.05 was regarded as statisti-
cally significant.
Results
Study objects
95 out of 111 eligible AFB sputum smear positive TB
patients were included in the study. The seroprevalence of
HIV was 38% (36/95, 14 M (male), 22 F (female), age 29
y (24–34)). 59 patients were HIV negative (28 M, 31 F, age
23 y (20–29)) (Table 1). Among eligible TB patients, 14%
(10/69) of HIV- patients and 14% (6/42) of the HIV+
patients were smokers and were excluded.
17 HC to smear positive TB patients were included (5 M,
12 F, age 25 y (21–35)). The excluded HC (n = 4) con-
sisted of one subject who did not return for the FeNO and
uNO measurements and three subjects with pathological
chest x-ray findings: one with TB, one with pneumonia
and one with a nodular infiltrate. Five HC and one BD did
not bring a morning urine sample but were still included
and analyzed on the group level of FeNO. In the group of
BD (n = 63), 17 subjects were excluded: four were HIV
positive (6%), three were found to be treated by antibiot-
ics, three had a family member treated for TB, one had
asthma, one had cough and five did not return for their
morning FeNO measurement or to leave a urine sample.
In total, 46 BD were included (35 M, 11 F, age 26 y (20–
37)). BCG vaccination coverage based on the presence of
a BCG scar was low in general (Table 1).
Clinical data
The clinical data are presented in Table 1. There were no
differences between HIV+/TB and HIV-/TB patients with
regards to the duration and presence of clinical symptoms
such as cough and haemoptysis. HIV+/TB patients had
significantly increased sedimentation rate compared to
HIV-/TB patients (83 mm/h (70–98) vs. 68 mm/h (47–
80), p < 0.001). The body mass index (BMI) was relatively
low both in the HIV-/TB and HIV+/TB patients (16.3 kg/
m2 (15.5–18.4) vs. 16.4 kg/m2 (14.7–18.1)) with an esti-
mated weight loss of 5.0 kg (3.0–8.0) vs. 6.0 kg (3.3–9.3).
HIV+/TB patients had significantly less advanced findings
on chest x-ray than HIV-/TB patients when the x-ray find-
ings were transferred to a semi quantitative scale from 0
(normal) to 3 (far advanced) (p = 0.019) (table 1).
L-Arginine, TNF-alpha and IL-12 in TB patients
Levels of L-arginine in plasma samples from 55 HIV neg-
ative and 31 HIV+/TB patients were determined by HPLC.
Serum levels of the pro-inflammatory cytokines TNF-
alpha and IL-12 were measured in a subset of the patients.
There was no difference in arginine levels between the two
groups (61.1 μM (49.3–78.4) vs. 57.7 μM (49.2–76.8)).
Regarding IL-12, there was a trend towards increased lev-
els in HIV-/TB patients (2.1 pg/ml (0.8–5.8), n = 23 vs. 0.9
(0.8–10.9), n = 11; p = 0.07). There was no difference in
the levels of TNF-alpha between the groups (HIV-/TB; 6.7
pg/ml (5.1–12.0), HIV+/TB; 8.3 (5.3–11.2)).BMC Infectious Diseases 2008, 8:146 http://www.biomedcentral.com/1471-2334/8/146
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Exhaled NO
Levels of FeNO in HIV+/TB patients (14.2 ppb (11.3–
19.3), n = 36) were significantly lower than in BD (17.7
ppb (13.1–27.4), n = 46, p = 0.013) and HC (18.7 ppb
(16.4–27.4), n = 17, p = 0.034) but did not differ from
those of HIV-/TB patients (14.3 ppb (10.8–24.0), n = 59)
(Figure 1). However, there was a significantly higher pro-
portion of patients with FeNO levels above 25 ppb in the
HIV-/TB group compared to HIV+/TB patients (29% (14/
49) vs. 8% (2/24), p = 0.05). In the HIV-/TB patients with
FeNO levels > 25 ppb there were no differences with
regards to sputum smear score, chest x-ray grade or BMI
compared to the HIV-/TB patients with FeNO levels < 25
ppb. Although not statistically significant, there was a
trend for increased uNO levels in HIV-/TB patients with
FeNO > 25 ppb compared to those with FeNO < 25 ppb
(1684 vs. 1147 μM, p = 0.140). Measurements of FeNO
performed on two consecutive mornings in the blood
donors showed a strong correlation (r2 = 0.862, n = 22)
(Figure 2). No correlation was found between FeNO and
grading of chest x-ray findings, sedimentation rate, levels
of arginine, TNF-alpha, IL-12 or clinical symptoms.
Urine NO-
2/NO-
3
Morning urine samples were collected in order to analyze
the levels of urinary NO metabolites. HIV+/TB patients
were found to have significantly higher levels of urinary
NO2 
-/NO3
-  compared to HIV-/TB patients (1431 μM
(1044–1991), n = 35, vs. 990 μM (593–1562), n = 58, p =
0.009). HC and BD had higher levels of urinary NO2
-/
NO3
- than HIV-/TB patients (1832 μM (964–2775), n =
12, p = 0.030 and 1394 μM (1000–1939), n = 45, p =
0.034) (Figure 3). No correlation was found between
uNO and FeNO in any of the groups.
Discussion
The level of production and especially the relative impor-
tance of nitric oxide in the host defense in human TB
remain controversial. There is a lack of clinical studies
describing the local production of nitric oxide in smear-
positive TB outpatients in high endemic areas with and
without HIV co-infection. Here, we have used a new FDA-
approved methodology which is routinely used in asth-
matic patients [9,10], to measure NO in exhaled air. We
found that in HIV positive TB patients there was a lower
proportion of subjects with increased FeNO levels (> 25
ppb) and a higher level of urinary nitric oxide metabolites
than in HIV negative TB patients. Moreover, in general,
patients with sputum smear positive TB had low levels of
exhaled nitric oxide compared to control subjects and
household contacts.
During active tuberculosis iNOS-mediated generation of
NO in alveolar macrophages has been shown [14,19] and
elevated levels of FeNO have been recorded in TB patients
without HIV co-infection or malnutrition [14]. This is in
Table 1: Baseline characteristics of study subjects
HIV-/TB HIV+/TB HC BD
n = 59 n = 36 n = 17 n = 46
Age (years) 23 (20–29) 29 (24–34) 25 (21–35) 26 (20–37)
Sex 
Female 31 22 12 11
Male 28 14 5 35
BCG vaccination scar (%) 78 1 8 7
Family member treated for TB (%) 25 36 100 0
X-ray n = 53 n = 33
Normal (%) 0 3
Minimal TB (%) 21 36
Moderately advanced TB (%) 49 49
Far advanced TB (%) 30 12*
Sedimentation rate (mm/h) 68 (47–80) 83 (70–98)*
Body mass index (kg/m2) 16.3 (15.5–18.4) 16.4 (14.7–18.1)
Estimated weight loss (kg) 5.0 (3.0–8.0) 6.0 (3.3–9.3)
Temperature (°C) 37.7 (37.2–38.3) 37.9 (37.3–38.5)
Fever (%) 90 100
Fever (weeks) 8.0 (4.0–12.0) 8.4 (4.0–12.0)
Cough (weeks) 10.0 (4.0–16.0) 8.0 (4.0–13.0)
Haemoptysis (%) 27 27
Haemoptysis (weeks) 0.0 (0.0–0.3) 0.0 (0.0–0.2)
Data are presented as median and inter quartile range. TB (tuberculosis), HIV (human immunodeficiency virus), HC (household contacts), BD 
(blood donors), BCG (bacillus Calmette-Guérin), SR (sedimentation rate). * p < 0.05 between HIV-/TB and HIV+/TB patients.BMC Infectious Diseases 2008, 8:146 http://www.biomedcentral.com/1471-2334/8/146
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contrast to the results of the present study which consists
of DOTS patients in sub Saharan Africa where most TB
patients are treated. HIV- and HIV+/TB patients both had
lower levels of FeNO compared to their household con-
tacts and blood donors. Nutritional status could be one
explanation for the differences since patients with poor
nutritional status were excluded in the previous study
measuring FeNO [14].
We found lower levels of arginine in plasma samples from
TB patients, both HIV positive and HIV negative, com-
pared to healthy individuals (119 μM) from a previous
study in the same area [20]. A recent report showed
increased arginase activity in TB patients which could be
part of the explanation for a local arginine deficiency in
TB [21]. In this study we found no correlation between
low levels of arginine and FeNO in TB patients at treat-
ment initiation. However, it has been shown that supple-
mentation of arginine during anti-TB chemotherapy
improved clinical outcome and increased arginine levels
in HIV-/TB patients [7]. This improvement could be due
to an increased NO production, but this hypothesis needs
to be confirmed by monitoring NO production during
arginine supplementation.
Although both blood donors, household contacts and
HIV+/TB patients had significantly increased levels of
uNO compared to HIV-/TB patients, our findings of
higher uNO levels in HIV+/TB patients compared to HIV-
/TB patients are in accordance with a previous study in the
same area [15]. It has been shown that HIV+ patients
without TB have increased serum nitrate where serum
nitrate levels correlated to amount of HIV/DNA in periph-
eral blood mononuclear cells [22], and that cultured
human monocytes infected with HIV-1 expressed iNOS
accompanied by a significant production of NO [23]. This
might explain the higher levels of urinary NO metabolites
in HIV+/TB patients compared to HIV-/TB patients in our
population. In this study we found no correlation
between serum levels of the pro-inflammatory cytokines
IL-12 and TNF-alpha and FeNO or uNO levels in TB
regardless of HIV status, although there was a trend for
increased IL-12 levels in HIV negative patients.
Levels of exhaled NO (FeNO) Figure 1
Levels of exhaled NO (FeNO). Levels of exhaled NO (FeNO) in HIV-/TB patients (n = 59), HIV+/TB patients (n = 36), 
household contacts to smear positive TB patients (HC, n = 17) and blood donors (BD, n = 46) presented as median and inter-
quartile range. ppb (parts per billion). * (p < 0.05).
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The control group consisted of blood donors at Gondar
University Hospital, Ethiopia, who donate blood to hos-
pitalized relatives. Urinary levels of NO-
2/NO-
3 in this
group were higher than in a previous study in Ethiopia
(1465 μM (1000–1939), n = 45, vs. mean 1020 ± SD 471
μM, n = 22) [15]. A high exposure to Mtb in the commu-
nity could be an explanation for the high levels of NO in
this group. Measurements of FeNO were performed in the
morning and analysis of uNO was done on first morning
urine, to minimize the influence of diet [24]. Day-to-day
correlation when measuring FeNO at the same time of the
day was strong, which allowed us to compare the groups
using morning measurements.
There was no correlation between uNO and FeNO in any
of the groups indicating a difference in pulmonary NO
production and systemic NO production. To ascertain
that the levels of FeNO are indicative of the inflammatory
status of the lower airways, Wang et al [14] measured NO
directly at the level of the vocal cords, main carina, left
and right main bronchus and close to the lesion site in the
lungs of TB patients. These levels did not differ signifi-
cantly from the FeNO and correlated highly with FeNO.
Other studies have measured exhaled NO at multiple
expiratory flows to discriminate between different sources
of NO in the lung [25]. This has been used to detect alve-
olar NO in alveolitis, asthma and chronic obstructive pul-
monary disease [25] and indicates that higher expiratory
flow rates might be required to measure NO in the termi-
nal airways. We used a flow rate of 45–55 ml/s which is
recommended for asthma. As pulmonary TB infection is
mainly localized to the lung parenchyma [26], a high
expiratory flow rate may be needed to measure NO pro-
duction optimally in TB patients, but this might be diffi-
cult due to the general condition in acute TB.
The normal range of FeNO has been previously described
in a healthy European population and the suggested nor-
mal range was between 3.6–20.6 pbb in both males and
females [27]. Although the levels of FeNO in HIV+/TB
patients did not differ from those of HIV-/TB patients
there was a significantly higher proportion of patients
with FeNO levels above 25 ppb in the HIV-/TB group
compared to HIV+/TB patients. Interestingly, we found
elevated levels of uNO in the subgroup of HIV-/TB
patients with FeNO > 25 ppb and this data indicates that
Consecutive morning measurements of exhaled nitric oxide (FeNO) Figure 2
Consecutive morning measurements of exhaled nitric oxide (FeNO). Correlation (r2 = 0.862) between two consec-
utive morning measurements of exhaled nitric oxide (FeNO) in blood donors and household contacts (n = 22). All measure-
ments were performed between 8 am and 12 am. ppb (parts per billion).
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the production of NO in response to TB could be hetero-
geneous with a subgroup of patients responding with an
increased NO production that could be detected both by
FeNO and urinary NO metabolites. However, there were
no differences in sputum smear score, chest x-ray grade or
BMI at treatment initiation with regards to FeNO levels
that could support the hypothesis that the levels of FeNO
could be associated to the severity of disease. Larger clini-
cal studies including long term clinical follow up will be
essential to test this hypothesis thoroughly. We also noted
that HIV+/TB patients had significantly less advanced
findings on chest x-ray than HIV-/TB patients but no direct
correlation between chest x-ray findings and FeNO was
observed. The low levels of FeNO in HIV+/TB patients are
in agreement with results showing decreased FeNO in
HIV+ patients without TB [13]. In HIV-/TB patients we
found lower levels of both FeNO and uNO than in blood
donors and household contacts. Future prospective fol-
low up studies are needed to test the hypothesis that low
NO production in a household contact could be a risk fac-
tor for developing TB and whether a high NO production
on exposure could be protective against the disease.
Conclusion
Our study shows locally impaired NO production in the
lung but an increased general NO production in HIV co-
infected TB patients compared to HIV negative TB
patients. Low levels of FeNO compared to blood donors
and household contacts were observed in both HIV- and
HIV+/TB patients, but future studies are needed to con-
firm whether low FeNO levels could be a risk factor in
acquiring TB, or whether it is a cause of the disease. Mon-
itoring FeNO in TB patients or other vulnerable persons
such as household contacts in follow up studies could be
a way to identify people at risk of developing TB or to fol-
low up treatment with future NO-based therapeutic strat-
egies.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TSc, JI, AW, FM and DE carried out the laboratory investi-
gations and field work as well as took part in the design of
the project. TSc, DE and JI drafted the manuscript. AA, BA,
Levels of urinary nitrite and nitrate (NO2
-/NO3
-) Figure 3
Levels of urinary nitrite and nitrate (NO2
-/NO3
-). Levels of urinary nitrite and nitrate (NO2
-/NO3
-) in HIV-/TB patients 
(n = 58), HIV+/TB patients (n = 35), household contacts to smear positive TB patients (HC, n = 12) and blood donors (BD, n 
= 45) presented as median and interquartile range. * (p < 0.05).
0
500
1000
1500
2000
2500
3000
HIV-/TB HIV+/TB HC BD
N
i
t
r
i
t
e
/
N
i
t
r
a
t
e
 
(
μ
M
)
*
*
*Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2008, 8:146 http://www.biomedcentral.com/1471-2334/8/146
Page 8 of 8
(page number not for citation purposes)
ED, EM, GA and YW participated in the inclusion and
monitoring of patients and the design of the project. GA
read the chest x-ray films. AG performed the analysis and
interpretation of TNF-alpha and IL-12. TSu and TF took
part in the analysis of arginine, the design of the project
and the interpretation of data. FM, OS and SB participated
in the design and coordination as well as contributed to
the drafting of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors wish to thank; Nurse Meseret Senbeto, Ms Saba Ekubay, Mr 
Belay Anagaw and Dr Asfawossen Yohannes for invaluable support in mon-
itoring patients and handling patient samples; Nurse Yohannes Mikena and 
Ato Alemnigus Yigzaw with colleges for the job at the blood bank and Dr 
Yenew Kebede for translating the study information. This study was sup-
ported by SIDA (Minor Field Studies), SAREC/SIDA, the Swedish Research 
Council, Swedish Heart and Lung Foundation (Oscar II Jubileé Foundation) 
and the Groschinskys Memorial Foundation.
References
1. WHO Metacentre: Fact sheets, Tuberculosis 2007 [http://www.who.int/
mediacentre/factsheets/fs104/en/index.html].
2. Russell DG: Mycobacterium tuberculosis: here today, and
here tomorrow.  Nature reviews, Molecular cell biology 2001, 2:1-9.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione
MC, Dye C: The growing burden of tuberculosis. Global
trends and interactions with the HIV epidemic.  Arch Intern
Med 2003, 163:1009-1021.
4. Lawn SD, Butera ST, Shinnick TM: Tuberculosis unleashed: the
impact of human immunodeficiency virus infection on the
host granulomatous response to Mycobacterium tuberculosis.
Microbes and Infection 2002, 4:635-646.
5. Chan ED, Chan J, Schluger NW: What is the role of nitric oxide
in murine and human host defense against tuberculosis ?
Current knowledge.  Am J Respir Cell Mol Biol 2001, 25:606-612.
6. Änggard E: Nitric oxide: mediator, murderer and medicine.
Lancet 1994, 343:1199-1206.
7. Schön T, Elias D, Moges F, Melese E, Tessema T, Stendahl O, Britton
S, Sundqvist T: Arginine as an adjuvant to chemotherapy
improves the clinical outcome in active tuberculosis.  Euro-
pean Respiratory Journal 2003, 21:483-488.
8. Ellis G, Adatia I, Yazdanpanah M, Makela SK: Nitrite and nitrate
analyses: a clinical biochemistry perspective.  Clinical Biochemis-
try 1998, 31(4):195-220.
9. American Thoracic Society Documents: ATS/ERS recommenda-
tions for standardized procedures for the online and offline
measurement of exhaled lower respiratory nitric oxide and
nasal nitric oxide, 2005.  Am J Respir Crit Care Med 2005,
171:912-930.
10. Stirling RG, Kharitonov SA, Campbell D, Robinson DS, Durham SR,
Chung KF, Barnes PJ: Increase in exhaled nitric oxide levels in
patients with difficult asthma and correlation with symp-
toms and disease severity despite treatment with oral and
inhaled corticosteroids.  Thorax 1998, 53:1030-1034.
11. Kharitonov SA, Yates D, Barnes PJ: Increased nitric oxide in
exhaled air of normal human subjects with upper respiratory
tract infections.  European Respiratory Journal J 1995, 8(2):295-297.
12. Grasemann H, Michler E, Wallot M, Ratjen F: Decreased concen-
tration of exhaled nitric oxide (NO) in patients with cystic
fibrosis.  Pediatric Pulmonology 1997, 24:173-177.
13. Loveless MO, Phillips CR, Giraud GD, Holden WE: Decreased
exhaled nitric oxide in subjects with HIV infection.  Thorax
1997, 52:185-186.
14. Wang CH, Liu CY, Lin HC, Yu CT, Chung KF, Kuo HP: Increased
exhaled nitric oxide in active pulmonary tuberculosis due to
inducible NO synthase up regulation in alveolar macro-
phages.  European Respiratory Journal 1998, 11:809-815.
15. Schön T, Gebre N, Sundqvist T, Aderaye G, Britton S: Effects of HIV
co-infection and chemotherapy on the urinary levels of nitric
oxide metabolites in patients with pulmonary tuberculosis.
Scand J Infect Dis 1999, 31:123-126.
16. Verdon CP, Burton BA, Prior RL: Sample pre-treatment with
nitrate reductase and glucose-6-phosphate dehydrogenase
quantitatively reduces nitrate while avoiding interference by
NADP+ when the Griess reaction is used to assay for nitrite.
Analytical Biochemistry 1995, 224:502-508.
17. Carlberg M: Assay of neuronal nitric oxide synthase by HPLC
determination of citrulline.  J Neurosc Met 1994, 52:165-167.
18. American Thoracic Society, National Tuberculosis Association of the
USA: Diagnostic standards and Classification of Tuberculosis.
New York: National Tuberculosis Association; 1961. 
19. Choi HS, Rai PR, Chu HW, Cool C, Chan ED: Analysis of nitric
oxide synthase and nitrotyrosine expression in human pul-
monary tuberculosis.  Am J Respir Crit Care Med 2002,
166:178-186.
20. Peters WH, Lubs H: Serum free amino acids of healthy males
and pregnant women from Ethiopia.  Die Nahrung 1987,
31:923-925.
21. Zea AH, Culotta KS, Ali J, Mason C, Park HJ, Zabaleta J, Garcia LF,
Ochoa AC: Decreased expression of CD3zeta and nuclear
transcription factor kappa B in patients with pulmonary
tuberculosis: potential mechanisms and reversibility with
treatment.  J Infect Dis 2006, 194(10):1385-1393.
22. Groeneveld PH, Kroon FP, Nibbering PH, Bruisten SM, van Swieten
P, van Furth R: Increased production of nitric oxide correlates
with viral load and activation of mononuclear phagocytes in
HIV-infected patients.  Scand J Infect Dis 1996, 28:341-345.
23. Bukrinsky MI, Nottet HSLM, Schmidtmayerova H, Dubrovsky L, Flan-
agan CR, Mullins ME, Lipton SA, Gendelman HE: Regulation of
nitric oxide synthase activity in human immunodeficiency
virus type 1 (HIV-1)-infected monocytes: Implications for
HIV-associated neurological disease.  J Exp Med 1995,
181:735-745.
24. Zetterquist W, Pedroletti C, Lundberg JO, Alving K: Salivary con-
tribution to exhaled nitric oxide.  European Respiratory Journal
1999, 13(2):327-33.
25. Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA:
Exhaled nitric oxide from lung periphery is increased in
COPD.  European Respiratory Journal 2005, 26:52-59.
26. Fitzgerald D, Haas DW: Mycobacterium tuberculosis.  In Mandell,
Douglas and Bennett's principles and practice of infectious diseases 6th
edition. Edited by: Mandell GL, Bennett JE, Dolin R. Elsevier Science,
Philadelphia, Pennsylvania; 2005.  2855, 2859, 2865–2866.
27. Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C,
Malerba M: Reference values for exhaled nitric oxide (reveno)
study.  Respir Res 2006, 30(7):94.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/8/146/pre
pub